These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 5355888)

  • 1. The intensified drug inspection program: procedures and results.
    Clevenger WL
    Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888
    [No Abstract]   [Full Text] [Related]  

  • 2. Biopharmaceutic equivalency and the role of the Food & Drug Administration.
    Hodges RM
    Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA-USP drug product problem reporting program--an update.
    Wheatley LS
    Hosp Formul; 1979 Mar; 14(3):359-60, 365. PubMed ID: 10316797
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety: the viewpoint of the pharmaceutical manufacturing industry.
    Wigle WW
    Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099
    [No Abstract]   [Full Text] [Related]  

  • 5. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 6. How good are our drugs?
    Miller LC
    Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276
    [No Abstract]   [Full Text] [Related]  

  • 7. Upon closer inspection. As the U.S. imports more drugs and devices, the FDA's overseas initiatives aim to head off trouble at the source.
    Rhea S
    Mod Healthc; 2009 Mar; 39(13):28-30. PubMed ID: 19405431
    [No Abstract]   [Full Text] [Related]  

  • 8. Planning for change.
    Hansen DC
    Bull Parenter Drug Assoc; 1969; 23(1):1-5. PubMed ID: 5765717
    [No Abstract]   [Full Text] [Related]  

  • 9. LyphoMed sparks worries.
    Wagner M
    Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202
    [No Abstract]   [Full Text] [Related]  

  • 10. Toward more effective drug regulation.
    Schmidt AM
    FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532
    [No Abstract]   [Full Text] [Related]  

  • 11. What's best for the patient?
    Burkle WS
    Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359
    [No Abstract]   [Full Text] [Related]  

  • 12. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
    Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805
    [No Abstract]   [Full Text] [Related]  

  • 13. The drug efficacy study.
    Provost GP
    Am J Hosp Pharm; 1968 Sep; 25(9):483. PubMed ID: 5671558
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA inspections of large volume and small volume parenteral manufacturers.
    Shepherd RE
    Bull Parenter Drug Assoc; 1976; 30(5):209-13. PubMed ID: 974306
    [No Abstract]   [Full Text] [Related]  

  • 15. The drug-potency question.
    Walker JM
    US Navy Med; 1974 Aug; 64(2):26-30. PubMed ID: 4534296
    [No Abstract]   [Full Text] [Related]  

  • 16. Reporting drug defects.
    Belson JJ
    Hosp Formul; 1975 Feb; 10(2):78-9. PubMed ID: 10316674
    [No Abstract]   [Full Text] [Related]  

  • 17. Public standards for drugs: reflections on their use by the professions and industry.
    Miller LC
    Hosp Formul; 1976 Mar; 11(3):151-5. PubMed ID: 1026682
    [No Abstract]   [Full Text] [Related]  

  • 18. New York State and drug lists: a history of confusion.
    Stetler CJ
    Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687
    [No Abstract]   [Full Text] [Related]  

  • 19. Assuring total drug quality.
    Simmons HE
    J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621
    [No Abstract]   [Full Text] [Related]  

  • 20. Securing the US pharmaceutical supply.
    Somberg JC
    Am J Ther; 2008; 15(3):197. PubMed ID: 18496255
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.